We conducted a retrospective review of 90 patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab (Herceptin®, Herzuma®, or Kanjinti®) between January 2020 and January 2025 at Queen Mary Hospital, Hong Kong. This evidence concerns the gene ERBB2 and breast cancer.